COVID-19-associated coagulopathy: a concise review on pathogenesis and clinical implications

Infez Med. 2021 Mar 1;29(1):1-9.

Abstract

In this review, we summarize the possible mechanisms of COVID-19-associated coagulopathy and compare its features to other similar conditions. The recent COVID-19 pandemic has caused enormous mortality and morbidity worldwide. It is important to note that COVID-19-associated thrombotic events play a huge role in the morbidity of this disease. Interestingly, it has been observed that this complication may occur despite prophylactic anticoagulant therapy. Recent studies on COVID-19-associated coagulopathy revealed that the COVID-19-associated hypercoagulability is more frequently observed among those with a severe course of the disease. Various mechanisms have been suggested as explanations for this condition and possible underlying etiologies.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Blood Coagulation Disorders / etiology*
  • Blood Coagulation Disorders / metabolism
  • COVID-19 / blood
  • COVID-19 / complications*
  • Endothelium, Vascular / metabolism
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Hemostasis
  • Heparin / adverse effects
  • Humans
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Receptors, Interleukin-2 / blood
  • SARS-CoV-2* / pathogenicity
  • Thrombophilia / etiology
  • Thrombosis / etiology
  • Tumor Necrosis Factor-alpha / blood
  • Virus Internalization

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • Interleukin-6
  • Receptors, Interleukin-2
  • Tumor Necrosis Factor-alpha
  • fibrin fragment D
  • Interleukin-10
  • Heparin
  • Angiotensin-Converting Enzyme 2